WebDoctor Encyclopedia

Plasma-cell neoplasms

Plasma cell leukaemia

Plasma cell leukaemia is an aggressive form of plasma cell cancer in which myeloma cells circulate in the blood. It needs urgent treatment with modern myeloma drug combinations and, for fit patients, a stem cell transplant followed by maintenance.

Medically reviewed Last reviewed October 21, 2026

What is plasma cell leukaemia?

Plasma cell leukaemia (PCL) is a rare and aggressive blood cancer in which abnormal plasma cells circulate in large numbers in the bloodstream. Plasma cells are a type of white blood cell that normally make antibodies to fight infection.

In plasma cell leukaemia, one faulty plasma cell multiplies out of control, crowds the bone marrow and spills into the blood.

PCL belongs to the same family as multiple myeloma, the more common plasma cell cancer. In myeloma, the abnormal cells mostly stay in the bone marrow. In PCL they also travel in the blood and can settle in organs such as the liver, spleen and lymph nodes.

Experts now define PCL as myeloma with 5% or more abnormal plasma cells in a blood film (Fernandez de Larrea et al., 2021). The previous threshold was 20%.

There are two forms:

  • Primary PCL appears from the start, in a person not previously known to have myeloma.
  • Secondary PCL develops later, in someone who already has myeloma, usually after several treatments.

PCL develops in only a small share of people with myeloma, about 0.5-4% (Jung and Lee, 2022). It needs urgent, intensive treatment. Modern drug combinations followed by a stem cell transplant have improved survival, but the outlook remains poorer than in myeloma (Musto et al., 2025).

1. Key facts at a glance

Feature Details
Type of cancer Plasma cell neoplasm with circulating plasma cells
Definition Myeloma with 5% or more circulating plasma cells in the blood
Forms Primary (at diagnosis) and secondary (after myeloma)
How common 0.5-4% of people with myeloma
Typical age Usually 50s-60s; often a little younger than myeloma
Main features Anaemia, kidney problems, high calcium, organ enlargement
Main treatment Intensive drug combinations, stem cell transplant, maintenance
Median survival About 2 years without transplant; 3 years or more with transplant
Outlook Guarded; it is classed as ultra-high-risk disease

2. Types

Type Description Notes
Primary PCL Diagnosed at first presentation Most of the published treatment research concerns this form
Secondary PCL Arises in established myeloma Usually after several lines of treatment; outlook is especially poor

How the definition has changed

Period Definition
Older definition At least 20% plasma cells in the blood, or more than 2 x 10^9/L
IMWG definition from 2021 5% or more plasma cells in a blood smear, in someone who otherwise meets criteria for myeloma

The International Myeloma Working Group (IMWG) lowered the threshold because people with 5% or more circulating plasma cells did as badly as those meeting the older definition (Fernandez de Larrea et al., 2021).

How PCL differs from myeloma

Feature Plasma cell leukaemia Multiple myeloma
Plasma cells in the blood Many Few or none
Organ involvement Liver, spleen, lymph nodes and other sites more often Less common
Kidney failure More frequent Less frequent
Bone lesions Sometimes less prominent Common
High-risk genetic changes Common Less common
Speed of illness Rapid Usually slower

3. Causes and risk factors

The cause of PCL is unknown. It is not caused by lifestyle and is not passed on in families.

Factor Notes
Age Mostly affects people in later middle age
Existing myeloma Risk factor for secondary PCL
Genetic changes in the cancer cells Not inherited; arise in the plasma cells themselves

Genetic changes in the cancer cells

Change Notes
t(11;14) Common in PCL; may respond to venetoclax
t(4;14), t(14;16) High-risk changes
Deletion of 17p (TP53) Associated with poorer outlook
Gain of 1q Associated with poorer outlook
Complex karyotype Many changes at once

These changes are tested in the cancer cells, using FISH or other genetic methods, to help plan treatment. The association of t(11;14) with PCL makes BCL2 inhibitors such as venetoclax a possible targeted option (Gong et al., 2024).

4. How does it look

In the blood

Test Typical finding
Blood count Low haemoglobin and platelets; raised white cell count in some
Blood film Plasma cells visible under the microscope
Flow cytometry Counts and characterises the abnormal plasma cells
Paraprotein Abnormal antibody (M protein) in blood or urine; sometimes only light chains

In the bone marrow

The marrow is often packed with abnormal plasma cells. A bone marrow biopsy confirms the diagnosis and provides cells for genetic testing.

On scans

Test What it shows
Whole-body low-dose CT Bone damage
MRI Marrow and spinal involvement
PET-CT Disease outside the bones, such as in soft tissue or organs

5. Symptoms

Symptoms often appear quickly, over weeks.

Common symptoms

  • Tiredness and breathlessness from anaemia
  • Bone pain, often in the back or ribs
  • Frequent infections due to low normal antibodies
  • Bruising or bleeding from low platelets
  • Weight loss and fevers

Less common symptoms

Symptom Possible cause
Thirst, confusion, constipation High calcium
Passing less urine, swelling Kidney damage
Swollen abdomen or discomfort Enlarged liver or spleen
Enlarged lymph nodes Spread to nodes
Headache, confusion, nerve problems Spread to the brain or its lining, which is rare
Lumps under the skin Plasma cell tumours outside the bones

When to seek urgent help

Seek urgent medical attention for fever with low blood counts, confusion, severe back pain with weakness or numbness in the legs, or passing very little urine.

6. Diagnosis

Test Purpose
Full blood count and blood film Detects circulating plasma cells
Flow cytometry of blood Measures the percentage of plasma cells
Serum protein tests and free light chains Measure the abnormal antibody
Kidney function and calcium Detect organ damage
LDH and beta-2 microglobulin Reflect disease bulk and risk
Bone marrow biopsy with FISH Confirms diagnosis and detects genetic changes
Whole-body imaging Bone and extramedullary disease
Lumbar puncture If there are nervous system symptoms
Heart and lung assessment Before intensive treatment

Staging and risk

PCL is not staged like solid cancers. It is regarded as ultra-high-risk plasma cell disease from the start (Fernandez de Larrea et al., 2021). The team also assesses fitness for transplant, kidney function and genetic risk.

7. Treatment

Because PCL progresses rapidly, treatment should start immediately after diagnosis (Jung and Lee, 2022). Care is best given in a specialist haematology centre, and patients are encouraged to join clinical trials.

Phases of treatment

Phase Purpose Typical approach
Induction Rapidly reduce the disease Combinations including a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide), dexamethasone and often an anti-CD38 antibody (daratumumab)
Stem cell collection Harvest the patient’s own stem cells After a good response
Autologous stem cell transplant High-dose melphalan followed by return of stem cells Recommended for fit patients; sometimes done twice (tandem)
Allogeneic transplant Donor stem cells Considered in selected younger patients, usually within trials
Maintenance Delay relapse Lenalidomide, with or without a proteasome inhibitor

Maintenance after transplant may reduce early relapses (Jung and Lee, 2022). In recent trials, between about 7 and 9 in 10 patients responded to treatment, and median overall survival ranged from about 2 to 3 years (Gong et al., 2024).

A typical first year of treatment

Months What usually happens
Week 1 Diagnosis, urgent start of treatment, kidney and calcium care
Months 1-4 Induction cycles, often partly as an inpatient at first
Months 4-5 Stem cell collection
Months 5-7 Autologous transplant, with 2-4 weeks in hospital
Months 7-12 Recovery, then maintenance treatment begins

Targeted and newer treatments

Treatment Notes
Venetoclax Targets BCL2; an option for disease with t(11;14)
Bispecific antibodies Being studied, mainly at relapse
CAR T-cell therapy Being studied in PCL
Intensive chemotherapy combinations (for example VTD-PACE) Used for rapid disease control in some centres

Supportive care

Problem Treatment
Kidney damage Fluids, rapid control of the disease, sometimes dialysis
High calcium Fluids, bisphosphonates or denosumab
Infection risk Antibiotic and antiviral prevention, vaccinations, immunoglobulin replacement
Bone pain and fractures Painkillers, bone-strengthening drugs, radiotherapy, surgery
Blood clots Preventive blood thinners with some drugs
Tumour lysis syndrome Fluids and drugs to protect the kidneys at the start of treatment

Side effects

Treatment Possible side effects
Bortezomib Nerve damage (tingling, numbness), shingles risk
Lenalidomide Low blood counts, clots, rash, diarrhoea
Daratumumab Infusion reactions, infections
Dexamethasone Mood changes, sleep problems, high blood sugar
High-dose melphalan and transplant Mouth ulcers, nausea, severe infection risk for 2-3 weeks

8. Outlook (prognosis)

PCL remains the most aggressive plasma cell cancer (Musto et al., 2025). The European Myeloma Network reports that people treated with modern drug combinations who cannot have a transplant may survive a median of up to 2 years. Those who do have transplant procedures may survive a median of 3 years or more.

Factor Effect on outlook
Fitness for transplant Transplant is linked with longer survival
Deep response to induction Better outcome
High-risk genetic changes Poorer outcome
Secondary PCL Poorer outlook than primary PCL
Kidney failure or high LDH Poorer outlook
Access to clinical trials Offers newer treatments

These are averages. Some patients live much longer, and outcomes are improving as new treatments become available.

9. Follow-up

Follow-up Purpose
Blood tests every 4-8 weeks Paraprotein, light chains, blood counts and kidney function
Bone marrow tests Check response and measurable residual disease
Imaging When symptoms or tests suggest progression
Vaccination review Re-vaccination after transplant
Monitoring for side effects Nerve damage, clots, infections, second cancers

10. Living with plasma cell leukaemia

  • Report fever promptly, especially during treatment, as infections can become serious quickly
  • Drink plenty of fluids to protect your kidneys, unless told otherwise
  • Avoid anti-inflammatory painkillers such as ibuprofen, which can harm the kidneys
  • Keep active within your limits; physiotherapists can advise on safe exercise with bone disease
  • Look after your teeth, particularly if you receive bone-strengthening drugs
  • Ask about clinical trials at diagnosis and at relapse
  • Seek support from myeloma charities, which also support people with PCL

For family members and carers

  • Learn the warning signs of infection and when to call the hospital
  • Help with transport to frequent appointments
  • Look after your own health, and ask about carer support services
  • Keep a shared list of medicines, appointments and contact numbers

11. Frequently asked questions

Question Answer
Is plasma cell leukaemia the same as myeloma? It is closely related but more aggressive, with many cancer cells in the blood
Is it the same as other leukaemias? No; it is a plasma cell cancer, treated with myeloma drugs
Can it be cured? Cure is rare, but treatment can control it, sometimes for years
Will I need a stem cell transplant? It is recommended if you are fit enough
Why does treatment start so quickly? The disease can damage organs within weeks
Is it inherited? No; my children do not need special tests
What is measurable residual disease? A highly sensitive test showing whether tiny amounts of cancer remain after treatment
Will I lose my hair? Not with most myeloma drugs, but usually after high-dose melphalan, temporarily
Can I work during treatment? Some people can, but many need time off, especially around transplant

12. Questions to ask your care team

  • Do I have primary or secondary PCL?
  • What genetic changes do the cancer cells have?
  • Which treatment combination do you recommend, and why?
  • Am I suitable for a stem cell transplant?
  • Is there a clinical trial I could join?
  • How can I reduce my risk of infection?
  • What support is available for me and my family?
  • Who should I call out of hours if I feel unwell?
  • How will we know whether the treatment is working?

Resources

  1. Fernandez de Larrea, C. et al. (2021) ‘Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage’, Blood Cancer Journal, 11(12), 192.
  2. Gong, Z. et al. (2024) ‘Current status on management of primary plasma cell leukemia’, Current Oncology Reports, 26(9), pp. 1104-1112.
  3. Jung, S.H. and Lee, J.J. (2022) ‘Update on primary plasma cell leukemia’, Blood Research, 57(S1), pp. 62-66.
  4. Musto, P. et al. (2025) ‘European Myeloma Network Group review and consensus statement on primary plasma cell leukemia’, Annals of Oncology, 36(4), pp. 361-374.
  5. National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.